"Xifaxan Prescribing Information, datasheet", March 2008 (2008-03-01), XP008139843, Retrieved from the Internet <URL:http://www.salix.com/assets/pdf/prescribe_into/xifaxanpi.pdf> (B1)

ZENEROLI MARIA LUISA ET AL: "Management of Hepatic Encephalopathy: Role of Rifaximin", CHEMOTHERAPY, S. KARGER AG, CH, vol. 51, no. suppl. 1, 1 April 2005 (2005-04-01), pages 90 - 95, XP008148562, ISSN: 0009-3157, DOI: 10.1159/000081994 (B1)

BAKER: "Current FDA-related drug information", HOSPITAL PHARMACY, vol. 38, no. 6, 2003, pages 582 - 597, XP008139842 (B1)

BASS ET AL: "Emerging therapies for the management of hepatic encephalopathy", SEMINARS IN LIVER DISEASE, THIEME MEDICAL PUBLISHERS, US, vol. 27, no. suppl. 2, 1 August 2007 (2007-08-01), pages 18 - 25, XP008148563, ISSN: 0272-8087, DOI: 10.1055/S-2007-984575 (B1)

BASS N M: "Review article: the current pharmacological therapies for hepatic encephalopathy.", ALIMENTARY PHARMACOLOGY & THERAPEUTICS FEB 2007 LNKD- PUBMED:17295849, vol. 25 Suppl 1, February 2007 (2007-02-01), pages 23 - 31, XP002669397, ISSN: 0269-2813 (B1)

GINTANT ET AL.: "Utility of hERG Assays as Surrogate Markers of Delayed Cardiac Repolarization and QT Safety", TOXICOLOGIC PATHOLOGY, vol. 34, 2006, pages 81 - 90, XP008139844 (B1)

LEEVY CARROLL B ET AL: "Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.", DIGESTIVE DISEASES AND SCIENCES MAR 2007 LNKD- PUBMED:17245628, vol. 52, no. 3, March 2007 (2007-03-01), pages 737 - 741, XP002669396, ISSN: 0163-2116 (B1)

MA ET AL.: "Rifaximin Is a Gut-Specific Human Pregnane X Receptor Activator", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 322, no. 1, 2007, pages 396, XP002601522 (B1)

PAIK ET AL.: "Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study", YONSEI MEDICAL JOUMAL, vol. 46, no. 3, June 2005 (2005-06-01), pages 399 - 407, XP008139597 (B1)

R WILLIAMS ET AL: "Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.", EUR J GASTROENTEROL HEPATOL, vol. 12, no. 2, 1 February 2000 (2000-02-01), pages 203 - 208, XP055408536 (B1)

ROMERO-GOMEZ: "Critical flicker frequency: It is time to break down barriers surrounding minimal hepatic encephalopathy", JOURNAL OF HEPATOLOGY, vol. 47, 2007, pages 10 - 11, XP025320838 (B1)

SAAB ET AL.: "MELD Fails to Measure Quality of Life in LiverTransplant Candidates.", LIVER TRANSPLANTATION, vol. 11, no. 2, 2005, pages 218 - 223, XP008139608 (B1)

SALIX PHARMACEUTICALS ET AL: "Xifaxan Prescribing Information", 1 March 2008 (2008-03-01), pages 1 - 2, XP008139843, Retrieved from the Internet <URL:http://www.salix.com/assets/pdf/prescribe_into/xifaxanpi.pdf> [retrieved on 20110405] (B1)

US-A1- 2004 157 840 (B1)

US-A1- 2006 210 592 (B1)

US-B1- 6 562 629 (B1)

WO-A1-2009/108814 (B1)

BAJAJ ET AL.: "Minimal hepatic encephalopathy matters in daily life", WORLD J GASTROENTEROL., vol. 14, no. 23, 21 June 2008 (2008-06-21), pages 3609 - 3615, XP008139841 (B1)